Why the study?
Does atrial overdrive pacing terminate drug-resistant ventricular tachycardia in a patient with dilated cardiomyopathy?
Does atrial overdrive pacing terminate drug-resistant ventricular tachycardia in a patient with dilated cardiomyopathy?
Atrial overdrive pacing via an implanted pacemaker and external activator offers a potentially safer alternative to ventricular pacing for terminating drug-resistant ventricular tachycardia.
Answers are grounded in this paper and cite their sources.
May offer noninvasive VT termination option in select cases; single report leaves open efficacy, safety, and need for trials.
An atrial pacemaker was implanted in a patient who had dilated cardiomyopathy, sinus node dysfunction, and drug-resistant ventricular tachycardia (VT). VT episodes were terminated by atrial overdrive pacing using an implanted pacemaker and a newly developed hand-held external programmer/transmitter. Although successful cases of termination of intractable VT by ventricular pacing have recently been reported, the ventricular method might increase the risk of accelerating VT. Atrial overdrive pacing is a safer method since it minimizes the possibility of tachycardia acceleration and, combined with antiarrhythmic drugs, it appeared to be a unique and useful approach for the treatment of drug-resistant VT.
No takes yet. Share an insight, caveat, or question.
Tanabe et al. (1985) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: